Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Malaysian Genomics Resource Centre Bhd Equity-to-Asset?
Malaysian Genomics Resource Centre BhdXKLS:0155 47 Equity-to-Asset is 0.91 as of Jun. 2026, which is 8% above its 10-year median of 0.84. GuruFocus rates XKLS:0155 with a GF Score™ of 47/100 and a GF Value™ of RM0.31 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Malaysian Genomics Resource Centre Bhd ranks better than 94.79% on this metric.
XKLS:0155'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.42 Med: 0.84 Max: 0.96
Current: 0.91
During the past 13 years, the highest Equity to Asset Ratio of Malaysian Genomics Resource Centre Bhd was 0.96. The lowest was 0.42. And the median was 0.84.
XKLS:0155's Equity-to-Asset is ranked better than 94.79% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.6
vs XKLS:0155: 0.91
Malaysian Genomics Resource Centre Bhd (XKLS:0155) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Malaysian Genomics Resource Centre Bhd Equity-to-Asset Related Terms
Malaysian Genomics Resource Centre Bhd Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Malaysian Genomics Resource Centre Bhd Equity-to-Asset Chart
Malaysian Genomics Resource Centre Bhd Annual Data
XKLS:0155 vs TMO, DHR, NTRA: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Malaysian Genomics Resource Centre Bhd's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Malaysian Genomics Resource Centre Bhd Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Malaysian Genomics Resource Centre Bhd's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Malaysian Genomics Resource Centre Bhd's Equity-to-Asset falls into.
Malaysian Genomics Resource Centre Bhd Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Malaysian Genomics Resource Centre Bhd (XKLS:0155) has a Equity-to-Asset of 0.91 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Malaysian Genomics Resource Centre Bhd and its competitors. This is near median its historical median of 0.84. Over the past decade, Malaysian Genomics Resource Centre Bhd's Equity-to-Asset has ranged from 0.42 to 0.96. According to the industry distribution chart, Malaysian Genomics Resource Centre Bhd ranks #11 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 5.2%.
Is Malaysian Genomics Resource Centre Bhd's Equity-to-Asset too high?
Malaysian Genomics Resource Centre Bhd's current Equity-to-Asset of 0.91 is near median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 0.96. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.60. Malaysian Genomics Resource Centre Bhd's value of 0.91 is 51.7% above this industry median. Based on the distribution chart, Malaysian Genomics Resource Centre Bhd ranks #11 out of 211 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Malaysian Genomics Resource Centre Bhd has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Malaysian Genomics Resource Centre Bhd's Equity-to-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Malaysian Genomics Resource Centre Bhd ranks #11 out of 211 companies for Equity-to-Asset. This places Malaysian Genomics Resource Centre Bhd in the top 5% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.60. Malaysian Genomics Resource Centre Bhd's value of 0.91 is 51.7% above this benchmark. Historically, Malaysian Genomics Resource Centre Bhd's own Equity-to-Asset has ranged from 0.42 to 0.96 over the past decade. While the company's 10-year median is 0.84 vs. the industry median of 0.60, Malaysian Genomics Resource Centre Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.60, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Malaysian Genomics Resource Centre Bhd's current Equity-to-Asset of 0.91 is 51.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Malaysian Genomics Resource Centre Bhd and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Malaysian Genomics Resource Centre Bhd's current Equity-to-Asset is 0.91, which is near median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malaysian Genomics Resource Centre Bhd stock overvalued right now?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd (XKLS:0155) is currently considered Modestly Overvalued. The stock's GF Value™ is RM0.31, compared to a current price of RM0.37 — trading 17.7% above its estimated fair value. The current Equity-to-Asset is 0.91, which is near median its 10-year median of 0.84 and 51.7% above the Medical Diagnostics & Research industry median of 0.60. Malaysian Genomics Resource Centre Bhd's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Malaysian Genomics Resource Centre Bhd (XKLS:0155), the current Equity-to-Asset is 0.91 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Malaysian Genomics Resource Centre Bhd (XKLS:0155) Overvalued in 2026?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd stock appears to be overvalued.
The current stock price of RM0.37 is trading 17.7% above its estimated GF Value™ of RM0.31.
GuruFocus considers Malaysian Genomics Resource Centre Bhd to be Modestly Overvalued.
Key valuation signals for XKLS:0155:
Equity-to-Asset: 0.91 (near median its 10-year median of 0.84)
GF Value™: RM0.31 vs. price of RM0.37 (17.7% above fair value)
Industry Position: 51.7% above the Medical Diagnostics & Research median (#11 of 211)
No single metric tells the full story. See the XKLS:0155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Malaysian Genomics Resource Centre Bhd is a Malaysia-based company. The company's principal activities include enabling personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. It offers genome sequencing and analysis (GSA) services and genetic screening services (GSS). The group offerings include precision genetic screening, project-based analysis, and high-quality cell therapy and cosmeceutical products. The reportable segments of the Group derive their revenue from the provision of personalised and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services within the healthcare segment.
47GF Score
Get the complete analysis for XKLS:0155
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0155 has been successfully added to your 
